Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

NCT05430971 | Recruiting DMC

• 1 other identifier: IMMONC0002
• Study Type: observational
• Target: 200
• Locations: 14 countries
• Sites: 20

Brief Summary

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Outcome Measures

Primary Outcomes (1)

• Overall survival

  Time from diagnosis to death

  5 years

Secondary Outcomes (3)

• Complete remission rate

  5 years

• Mean duration of the first remission

  5 years

• Event-free survival

  5 years

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients with BPDCN diagnosed since 01.01.2010

You may qualify if:

• Diagnosis of BPDCN
• Signed informed consent form for prospective patients

Sponsors & Collaborators

• Immune Oncology Research Institute: lead

Study Sites (20)

Sylvester Comprehensive Cancer Center, University of Miami

Miami, Florida, 33136, United States

RECRUITING

Moffitt Cancer Center

Tampa, Florida, 33612, United States

RECRUITING

Seattle Children's Cancer and Blood Disorders Center

Seattle, Washington, 98145, United States

RECRUITING

Hematology Center named after prof. R. Yeolyan

Yerevan, 0014, Armenia

RECRUITING

University of Calgary

Calgary, Alberta, T2N 1N4, Canada

RECRUITING

Children's Hospital of Eastern Ontario, University of Ottawa

Ottawa, Ontario, K1H 8L1, Canada

RECRUITING

Cyprus Society of Haematology

Nicosia, 2019, Cyprus

RECRUITING

Oncology Center, Mansoura University Faculty of Medicine

Al Mansurah, 7650030, Egypt

RECRUITING

M. Iashvili Children's Central Hospital

Tbilisi, 0159, Georgia

RECRUITING

Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All India Institute of Medical Sciences

New Delhi, 110029, India

RECRUITING

Pediatric Hematology Oncology, Children's Welfare Teaching Hospital, Medical City, College of Medicine, University of Baghdad

Baghdad, 61023, Iraq

RECRUITING

University of Perugia - Azienda Ospedaliera Perugia

Perugia, 06129, Italy

RECRUITING

Department of Biomedicine and Prevention, University of Rome Tor Vergata

Roma, 00133, Italy

RECRUITING

Department of hematology, Kuwait Cancer Control Center

Kuwait City, 42262, Kuwait

RECRUITING

Fundeni Clinical Institute, Department of Acute Leukemia

Bucharest, 022328, Romania

RECRUITING

China Medical University Children's Hospital

Taichung, 40447, Taiwan

RECRUITING

Turkish Pediatric Cancer Registry

Ankara, 06690, Turkey (Türkiye)

RECRUITING

Istanbul University, Oncology Institute

Istanbul, 34093, Turkey (Türkiye)

RECRUITING

University of Health Sciences, Umraniye Research and Education Hospital, Pediatric Hematology and Oncology Department, Pediatric Bone Marrow Transplantation Unit

Istanbul, 34766, Turkey (Türkiye)

RECRUITING

Broomfield Hospital, Haematology Mid and South Essex University Hospitals Group

Chelmsford, Essex, CM1 7ET, United Kingdom

RECRUITING

MeSH Terms

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm

Condition Hierarchy (Ancestors)

Histiocytic Disorders, Malignant; Neoplasms by Histologic Type; Neoplasms; Leukemia; Lymphoma; Hematologic Neoplasms; Neoplasms by Site; Skin Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Astghik Voskanyan, MD

  Immune Oncology Research Institute, Yerevan, Armenia

  PRINCIPAL INVESTIGATOR

• Gevorg Tamamyan, MD, PhD, DSc

  Immune Oncology Research Institute, Yerevan, Armenia

  STUDY DIRECTOR

Central Study Contacts

Astghik Voskanyan, MD

CONTACT

+374 10 28 38 00; astghikvos@gmail.com

Karen Bedirian, MPH

CONTACT

+374 10 28 38 00; karenbedirian@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: OTHER
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 21, 2022
• First Posted: June 24, 2022
• Study Start: July 1, 2022
• Primary Completion (Estimated): July 1, 2032
• Study Completion (Estimated): July 1, 2032
• Last Updated: February 17, 2026

Record last verified: 2026-02

Locations

IR (1); CY (1); TW (1); TU (3); GB (1); AR (1); RO (1); US (3); EG (1); CA (2); IN (1); IT (2); GE (1); KU (1)